title: Safe injection practices for administration of propofol.
abstract: Sepsis and postoperative infection can occur as a result of unsafe practices in the administration of propofol and other injectable medications. Investigations of infection outbreaks have revealed the causes to be related to bacterial growth in or contamination of propofol and unsafe medication practices, including reuse of syringes on multiple patients, use of single-use medication vials for multiple patients, and failure to practice aseptic technique and adhere to infection control practices. Surveys conducted by AORN and other researchers have provided additional information on perioperative practices related to injectable medications. In 2009, the US Food and Drug Administration and the Centers for Disease Control and Prevention convened a group of clinicians to gain a better understanding of the issues related to infection outbreaks and injectable medications. The meeting participants proposed collecting data to persuade clinicians to adopt new practices, developing guiding principles for propofol use, and describing propofol-specific, site-specific, and practitioner-specific injection techniques. AORN provides resources to help perioperative nurses reduce the incidence of postoperative infection related to medication administration.
authors.affiliation: Outer Cape Health Services, Provincetown, MA, USA.
authors.forename: Cecil A
authors.initials: CA
authors.lastname: King
authors.forename: Mary
authors.initials: M
authors.lastname: Ogg
mesh_terms: D003428:Cross Infection / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D004196:Disease Outbreaks / Q000517:prevention & control; D004340:Drug Contamination / Q000517:prevention & control*; D017743:Equipment Reuse; D006801:Humans; D017053:Infection Control / Q000379:methods*; D007267:Injections / Q000379:methods*; D017410:Practice Guidelines as Topic; D015742:Propofol / Q000008:administration & dosage*; D018805:Sepsis / Q000517:prevention & control*; D013594:Syringes / Q000009:adverse effects; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D015742:Propofol